Table 1 Summary of patient characteristics
From: mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
Treatment group | Number of patients | Mean age (range) | Pre- vs post menopausal ratio | %White | % Other race | % Hispanic White | % ER +  | % PR +  | % Undetermined hormonal status |
|---|---|---|---|---|---|---|---|---|---|
Control | 18 | 53(33–76) | 8:10 | 88 | 12 | 60 | 67 | 50 | 22 |
Sirolimus | 27 | 59(42–79) | 6:21 | 85 | 15 | 62 | 89 | 81 | 11 |
P-value |  | 0.0681 | 0.1883 |  > 0.9999 | 0.5338 | 0.1294 | 0.0772 | 0.4002 | |